Yourgene Health, part of the Novacyt Group, has commercially launched its IVDR-certified Yourgene Insight DPYD assay, expanding its molecular diagnostics portfolio for clinical laboratories across regulated European markets. The new…
Myriad Genetics is expanding access to its faster hereditary cancer testing to include patients diagnosed with ovarian and endometrial cancer, broadening the reach of its genetic testing services as the…
Caris Life Sciences has launched a new national awareness campaign featuring actor, director and producer Kevin Costner as the company looks to bring greater public attention to the importance of…
Massachusetts is strengthening its position as a major life sciences hub, but the sector's expansion is bringing a new challenge: finding enough workers with the technical and analytical skills required…
MedGenome has introduced OncoTrack MRD, a personalised molecular residual disease test designed to give oncologists a more detailed view of cancer after diagnosis and treatment. The new test uses tumour-informed…
A new discovery from researchers in Australia could change how inflammatory bowel disease is understood and treated, after scientists identified a molecular abnormality in gut tissue that appears before visible…
The World Health Organization (WHO) is stepping up efforts to improve the availability of treatment for children and adolescents living with sickle cell disease, with a new focus on medicines…
The UK has opened a new testing environment for emerging medical technologies as regulators and healthcare providers seek to close the gap between promising products and their practical use in…
BillionToOne has expanded its liquid biopsy portfolio with the launch of Northstar Origin, a new test designed to help physicians determine where a cancer originated when the primary tumor cannot…
The Colorectal Cancer Alliance and Abbott have launched a new online resource aimed at helping Americans understand and complete at-home colorectal cancer screening tests. The initiative is designed to address…